New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
10:12 EDTNVGNNovogen Limited halted for volatility after jumping 83% to $4.24
News For NVGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
10:04 EDTNVGNNovogen says studies confirm Trilexium potential for child cancers
Novogen earlier today released the results of two recently-completed studies of one of its lead candidate compounds, TRX-E-009-1, confirming its ability to kill pediatric brain cancer cells - diffuse intrinsic pontine glioma and pediatric neuroblastoma cells - and clearing the way for the compound to come into the clinic as a potential treatment of childhood cancers, the company said. Novogen is developing Trilexium as a treatment for both primary and secondary brain cancer in adults. Novogen is planning to bring Trilexium into the clinic in late 2015 for the treatment of GBM, with a Phase 1 study planned for Australian hospitals. Australian researchers in the last week have now reported that TRX-E-009-1 is highly active in vitro against 3-dimensional spheroids of DIPG derived from patient biopsies, Novogen added.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use